» Articles » PMID: 21047676

Phosphodiesterase 4B is Essential for T(H)2-cell Function and Development of Airway Hyperresponsiveness in Allergic Asthma

Overview
Date 2010 Nov 5
PMID 21047676
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cyclic AMP (cAMP) signaling modulates functions of inflammatory cells involved in the pathogenesis of asthma, and type 4 cAMP-specific phosphodiesterases (PDE4s) are essential components of this pathway. Induction of the PDE4 isoform PDE4B is necessary for Toll-like receptor signaling in monocytes and macrophages and is associated with T cell receptor/CD3 in T cells; however, its exact physiological function in the development of allergic asthma remains undefined.

Objectives: We investigated the role of PDE4B in the development of allergen-induced airway hyperresponsiveness (AHR) and T(H)2-driven inflammatory responses.

Methods: Wild-type and PDE4B(-/-) mice were sensitized and challenged with ovalbumin and AHR measured in response to inhaled methacholine. Airway inflammation was characterized by analyzing leukocyte infiltration and cytokine accumulation in the airways. Ovalbumin-stimulated cell proliferation and T(H)2 cytokine production were determined in cultured bronchial lymph node cells.

Results: Mice deficient in PDE4B do not develop AHR. This protective effect was associated with a significant decrease in eosinophils recruitment to the lungs and decreased T(H)2 cytokine levels in the bronchoalveolar lavage fluid. Defects in T-cell replication, T(H)2 cytokine production, and dendritic cell migration were evident in cells from the airway-draining lymph nodes. Conversely, accumulation of the T(H)1 cytokine IFN-γ was not affected in PDE4B(-/-) mice. Ablation of the orthologous PDE4 gene PDE4A has no impact on airway inflammation.

Conclusion: By relieving a cAMP-negative constraint, PDE4B plays an essential role in T(H)2-cell activation and dendritic cell recruitment during airway inflammation. These findings provide proof of concept that PDE4 inhibitors with PDE4B selectivity may have efficacy in asthma treatment.

Citing Articles

Rutaecarpine alleviates hepatic ischemia‒reperfusion injury in liver transplantation by inhibiting inflammatory response and oxidative stress.

Liu Y, Qi F, Xiang L, Yi Z, Li S Front Pharmacol. 2025; 16:1539744.

PMID: 39963247 PMC: 11830625. DOI: 10.3389/fphar.2025.1539744.


PDE4B Modulates Phosphorylation of p65 (Ser468) via cAMP/PKA in Acute Lung Injury.

Dhar R, Li Y, Hu Z, Song S, Zhang Z, Ji J Lung. 2025; 203(1):33.

PMID: 39956855 DOI: 10.1007/s00408-025-00787-6.


Menisoxoisoaporphine A, a novel oxoisoaporphine alkaloid from Menispermi Rhizoma, inhibits inflammation by targeting PDE4B.

Qiao X, Cao X, Xu S, Wang C, Guo R, Yao X Front Pharmacol. 2024; 15:1505116.

PMID: 39691395 PMC: 11649434. DOI: 10.3389/fphar.2024.1505116.


Targeting pro-inflammatory T cells as a novel therapeutic approach to potentially resolve atherosclerosis in humans.

Fan L, Liu J, Hu W, Chen Z, Lan J, Zhang T Cell Res. 2024; 34(6):407-427.

PMID: 38491170 PMC: 11143203. DOI: 10.1038/s41422-024-00945-0.


Dysregulated Cyclic Nucleotide Metabolism in Alcohol-Associated Steatohepatitis: Implications for Novel Targeted Therapies.

Montoya-Durango D, Walter M, Rodriguez W, Wang Y, Chariker J, Rouchka E Biology (Basel). 2023; 12(10).

PMID: 37887031 PMC: 10604143. DOI: 10.3390/biology12101321.


References
1.
Makela M, Kanehiro A, Borish L, Dakhama A, Loader J, Joetham A . IL-10 is necessary for the expression of airway hyperresponsiveness but not pulmonary inflammation after allergic sensitization. Proc Natl Acad Sci U S A. 2000; 97(11):6007-12. PMC: 18549. DOI: 10.1073/pnas.100118997. View

2.
Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben T, Karp C . Interleukin-13: central mediator of allergic asthma. Science. 1998; 282(5397):2258-61. DOI: 10.1126/science.282.5397.2258. View

3.
Naganuma K, Omura A, Maekawara N, Saitoh M, Ohkawa N, Kubota T . Discovery of selective PDE4B inhibitors. Bioorg Med Chem Lett. 2009; 19(12):3174-6. DOI: 10.1016/j.bmcl.2009.04.121. View

4.
Lipworth B . Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet. 2005; 365(9454):167-75. DOI: 10.1016/S0140-6736(05)17708-3. View

5.
Robichaud A, Stamatiou P, Catherine Jin S, Lachance N, Macdonald D, Laliberte F . Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest. 2002; 110(7):1045-52. PMC: 151147. DOI: 10.1172/JCI15506. View